Jove
Visualize
Contact Us
JoVE
x logofacebook logolinkedin logoyoutube logo
ABOUT JoVE
OverviewLeadershipBlogJoVE Help Center
AUTHORS
Publishing ProcessEditorial BoardScope & PoliciesPeer ReviewFAQSubmit
LIBRARIANS
TestimonialsSubscriptionsAccessResourcesLibrary Advisory BoardFAQ
RESEARCH
JoVE JournalMethods CollectionsJoVE Encyclopedia of ExperimentsArchive
EDUCATION
JoVE CoreJoVE BusinessJoVE Science EducationJoVE Lab ManualFaculty Resource CenterFaculty Site
Terms & Conditions of Use
Privacy Policy
Policies

Related Concept Videos

mTOR Signaling and Cancer Progression03:03

mTOR Signaling and Cancer Progression

3.7K
The mammalian target of rapamycin or mTOR protein was discovered in 1994 due to its direct interaction with rapamycin. The protein gets its name from a yeast homolog called TOR. The mTOR protein complex in mammalian cells plays a major role in balancing anabolic processes such as the synthesis of proteins, lipids, and nucleotides and catabolic processes, such as autophagy in response to environmental cues, such as availability of nutrients and growth factors.
The mTOR pathway or the...
3.7K

You might also read

Related Articles

Articles linked to this work by shared authors, journal, and citation graph.

Sort by
Same author

Bridging the Gap: Examining the Association of Travel Burden With Treatment Administration and Survival in Stage II/III Gastric Cancer.

JCO oncology practice·2026
Same author

CA19-9 induces microenvironment remodeling in pancreatic ductal adenocarcinoma.

bioRxiv : the preprint server for biology·2026
Same author

HDAC INHIBITION SENSITIZES PANCREATIC TUMORS TO DNA DAMAGE BY GLOBAL REDISTRIBUTION OF THE TRANSCRIPTIONAL MACHINERY.

bioRxiv : the preprint server for biology·2026
Same author

Clinical and molecular correlates of circulating tumor fraction in patients with metastatic pancreatic ductal adenocarcinoma.

Clinical cancer research : an official journal of the American Association for Cancer Research·2026
Same author

Targeting the αvβ5 Integrin Modifies the TGF-β-Rich Tumor Microenvironment of Pancreatic Cancer.

Cancer research·2026
Same author

Metabolic Salvage and Acyl-chain Remodeling Support Glycosphingolipid Synthesis within the PDAC Tumor Microenvironment.

bioRxiv : the preprint server for biology·2026

Related Experiment Video

Updated: Jun 4, 2025

Ultrasound-Guided Orthotopic Implantation of Murine Pancreatic Ductal Adenocarcinoma
06:21

Ultrasound-Guided Orthotopic Implantation of Murine Pancreatic Ductal Adenocarcinoma

Published on: November 19, 2019

11.0K

MICAL2 Promotes Pancreatic Cancer Growth and Metastasis.

Bharti Garg1, Sohini Khan1, Asimina S Courelli1

  • 1Division of Surgical Oncology, Department of Surgery, Moores Cancer Center, University of California, San Diego, La Jolla, California.

Cancer Research
|January 2, 2025
PubMed
Summary
This summary is machine-generated.

Researchers identified MICAL2 as a key gene in pancreatic cancer (PDAC) progression. Targeting MICAL2 may offer new therapeutic strategies for this deadly disease.

More Related Videos

Bioluminescent Orthotopic Model of Pancreatic Cancer Progression
09:25

Bioluminescent Orthotopic Model of Pancreatic Cancer Progression

Published on: June 28, 2013

26.8K
A Preclinical Murine Model of Hepatic Metastases
06:51

A Preclinical Murine Model of Hepatic Metastases

Published on: September 27, 2014

28.6K

Related Experiment Videos

Last Updated: Jun 4, 2025

Ultrasound-Guided Orthotopic Implantation of Murine Pancreatic Ductal Adenocarcinoma
06:21

Ultrasound-Guided Orthotopic Implantation of Murine Pancreatic Ductal Adenocarcinoma

Published on: November 19, 2019

11.0K
Bioluminescent Orthotopic Model of Pancreatic Cancer Progression
09:25

Bioluminescent Orthotopic Model of Pancreatic Cancer Progression

Published on: June 28, 2013

26.8K
A Preclinical Murine Model of Hepatic Metastases
06:51

A Preclinical Murine Model of Hepatic Metastases

Published on: September 27, 2014

28.6K

Area of Science:

  • Oncology
  • Molecular Biology
  • Epigenetics

Background:

  • Pancreatic ductal adenocarcinoma (PDAC) is a highly lethal cancer with limited effective therapies.
  • Identifying novel therapeutic targets is crucial for improving patient outcomes.

Purpose of the Study:

  • To characterize the super-enhancer (SE) landscape in human PDAC.
  • To identify novel, targetable drivers of PDAC progression.

Main Methods:

  • Super-enhancer profiling of human PDAC.
  • Gene expression analysis (MICAL2, KRAS, EMT markers).
  • Loss- and gain-of-function studies in PDAC cell lines and in vivo models.

Main Results:

  • MICAL2 identified as an SE-associated gene overexpressed in PDAC.
  • High MICAL2 expression correlates with poor patient prognosis.
  • MICAL2 promotes PDAC growth, metastasis, ERK1/2 and AKT activation, and inhibits macropinocytosis.

Conclusions:

  • MICAL2 is a critical driver of PDAC progression, influencing multiple oncogenic pathways.
  • MICAL2 represents a potential pharmacologic target for pancreatic cancer therapy.